Replimune Group

About:

Replimune Group develop the next generation of ‘oncolytic immunotherapies’ for the treatment of cancer.

Website: http://replimune.com/

Twitter/X: replimune

Top Investors: Hercules Capital, Cormorant Asset Management, Foresite Capital, Redmile Group, Atlas Venture

Description:

Replimune Group develop the next generation of ‘oncolytic immunotherapies’ for the treatment of cancer. Replimune is developing novel, proprietary products intended to improve both the direct anti-tumor effects of selective virus replication and the potency of the immune response to the tumor antigens released. The Company’s Immulytic™ platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune activating proteins to the tumor and draining lymph nodes. The approach is expected to be highly synergistic with immune checkpoint blockade and other approaches to cancer treatment. Replimune intends to progress these therapies rapidly through clinical trials and to combine with other immuno-oncology products with complementary mechanisms of action at an early stage.